As you’ve likely read, our founding director Matt Dun is a biomedical researcher focused on finding or developing therapy options for DIPG/DMG patients. Having known the hopelessness of hearing that his child’s cancer is ‘untreatable’, A/Prof Dun is determined to change the ‘go home and make memories’ paradigm that DIPG/DMG families currently face.
Leading the Cancer Signalling Research Group (CSRG) at The University of Newcastle, Hunter Medical Research Institute, Matt and his team use DIPG/DMG tumour samples to study how the cancer works – particularly the genes and proteins that control tumour cell growth, and its response (or resistance) to experimental therapies. The specialised techniques quality work and collaborative approach of Matt and his team have already helped bring treatment options to clinical trial – a fantastic achievement within 4 years of establishing the research program.
With a decorated career studying leukaemias prior to daughter Josephine’s DIPG diagnosis, Matt knows DIPG/DMG research can bring about improved patient outcomes, just as has been achieved in blood cancers in recent times. RUN DIPG are immensely proud to support the work of Matt and the ‘Dun Lab’ alongside other fantastic researchers dedicated to moving towards a cure.
Matt’s work can be seen via the below publications, and an overview via Google Scholar can be found here.
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma